New patent for the drug Boehringer Ingelheim SYNJARDY – DrugPatentWatch
Annual Drug Patent Expiration for SYNJARDY
Synjardy is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from a single supplier. There are seven patents protecting this drug and two Paragraph IV challenges.
SYNJARDY drug price trends.
Drug patent litigation for SYNJARDY.
This drug has one hundred and seventy-four patent family members in forty-four countries.
The generic material in SYNJARDY is empagliflozin; metformin hydrochloride. One registered supplier for this compound. Additional details are available on empagliflozin; metformin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in New patent for the Boehringer Ingelheim drug SYNJARDY
